Product logins

Find logins to all Clarivate products below.


Eosinophilic Esophagitis | Treatment Algorithms: Claims Data Analysis | US | 2020

Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus caused by an accumulation of eosinophils leading to a difficulty in swallowing food with the potential for dangerous food impaction. Topical steroids and proton pump inhibitors are the mainstays of clinical management for EoE, however the indication has no official therapy approvals by FDA. EoE has an active pipeline that will further drive off-label use until novel therapies with unique MOAs reach the market. As the EoE current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in EoE to help new players to better understand current treatment practices in EoE and help define the market niche for their emerging product.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed EoE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed EoE patients?
  • How have steroids and proton pump inhibitors been integrated into the treatment algorithm, and what are their source of business?
  • What percentage of EoE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of EoE patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geographies

United States

Real World data

Longitudinal patient-level claims data analysis

Key Drugs Covered

Fluticasone, budesonide, ciclesonide, prednisone, dexlansoprazole, omeprazole, esomeprazole, lansoprazole, rabeprazole, and pantoprazole

Key Analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…